



## Novel Substituted 4-Thiazolidinone, Synthesis and Antimicrobial Evaluation

\* Hanfi M.  
Ziauddin

P.G. Department of Chemistry, Yeshwant College Nanded (India)  
\* Corresponding Author

Seema I. Habib

Department of Chemistry, G.M.Momin Womens College, Bhiwandi (India)

### ABSTRACT

A series of novel 4-thiazolidinone were synthesized with the aim to synthesize the biologically active molecules via C condensation of Schiff bases and thioglycolic acid. These newly synthesized compounds were characterized by physical, chemical and spectral analysis data (IR, <sup>1</sup>H-NMR, Mass) and are further screened for their antimicrobial activity using different Antimicrobes.

**KEYWORDS :** Amlodipine Schiff bases, substituted 4-thiazolidinones, Antimicrobial Activity

### Introduction

In medicinal chemistry, 4-thiazolidinone has received an important role due to wide variety of physiological activities. A compound with biological activity is often derived from heterocyclic structure. Indeed one of the richest sources of diversity for the medicinal chemistry is small heterocyclic ring, which in addition to often exhibiting biological activity, may serve as rigid scaffolds for further display of functionalities.

In recent years, interests of researchers have been focused on the heterocyclic systems which contain various heteroatoms such as nitrogen, sulphur and oxygen, because of their biological importance.

4-Thiazolidinone derivatives have been demonstrated to act as antibacterial [1-10] and antiprotozoal [2], antifungal [11-14], anticonvulsant [15-19], anticancer [20-21], antituberculosis [22-28], antitumor [29-30] and antiparasitic, herbicidal agents [31-35], anti-inflammatory [36], and analgesic [37].

Literature survey shows that, 4-thiazolidinone of amlodipine Schiff bases are not synthesized and studied for their antimicrobial properties. Hence the present study was undertaken with the aim to synthesize new 4-thiazolidinones from amlodipine Schiff bases and studied their antimicrobial activities against different pathogens


### Materials and methods

#### Experimental


Melting points were uncorrected and determined in open capillaries. The purity of the compound is checked by TLC. The IR spectra were recorded on FTIR Shimadzu spectrometer, and <sup>1</sup>HNMR spectra were recorded on a Varian 300 MHz spectrometer (CDCl<sub>3</sub>) using TMS as an internal standard. Mass spectra were recorded on VG 70704 mass spectrometer at 70 eV.

#### Synthesis of Thiazolidinones:

To a solution of imine (1.0 gm, 0.001 mol) in dry benzene was added thioglycolic acid (0.18 gm, 0.001 mol). The contents were refluxed for 6h until completion of the reaction. Excess solvent was removed under reduced pressure and the residue was treated with saturated solution of NaHCO<sub>3</sub>, extracted with ethyl acetate, dried with Na<sub>2</sub>SO<sub>4</sub> and solvent was distilled off. The residue on re-crystallization gave 4-thiazolidinone



Where **R** is the substituted benzaldehyde



(3a-I)

The compounds (**3a-I**) were prepared by using the above procedure and their percentage yield and physical constants were recorded in Table II. Their structures have been confirmed by Mass, IR and <sup>1</sup>HNMR spectra.

**Table I: Physical data of the compounds (3a-I)**

Comp. No.	R <sub>1</sub>	R <sub>2</sub>	R <sub>3</sub>	R <sub>4</sub>	Yield (%)	M. P. (°C)
3a	H	H	OCH <sub>3</sub>	OCH <sub>3</sub>	78	165-167
3b	H	H	OH	NO <sub>2</sub>	79	113-115
3c	H	H	Br	OCH <sub>3</sub>	58	126-129
3d	H	H	F	Br	48	150-152
3e	H	H	H	Cl	86	102-104
3f	Cl	Cl	H	H	72	178-180
3g	H	H	H	F	59	137-142
3h	NO <sub>2</sub>	H	H	H	65	142-144
3i	Cl	H	H	H	66	134-136
3j	H	H	F	H	60	112-114
3k	H	NO <sub>2</sub>	H	Br	61	127-129
3l	Br	H	H	H	68	172-174

### Spectral analysis:

#### Compound (3i):

<sup>1</sup>HNMR: <sup>1</sup>HNMR spectra were recorded in DMSO-*d*<sub>6</sub> on a Varian AS instrument at 400 MHz using TMS as an internal standard.

(DMSO) δ ppm: 1.09 (t, 3H, CH<sub>3</sub>); 2.5 (s, 3H, CH<sub>3</sub>); 2.85 (m, 2H, CH<sub>2</sub>); 3.5 (s, 3H, OCH<sub>3</sub>); 3.52 (dd, 2H, CH<sub>2</sub>); 3.8 (dd, 2H, CH<sub>2</sub>); 3.97 (m, 2H, CH<sub>2</sub> methylene protons); 4.5 (dd, 2H, CH<sub>2</sub>); 5.27 (s, 1H, CH); 6.18 (s, 1H, thiazolidinone proton); 7.0-7.7 (m, 8H, aromatic proton); 8.49 (s, 1H, N-H)

**(DMSO+D<sub>2</sub>O) δ ppm:**1.09 (t, 3H, CH<sub>3</sub>);2.5(s, 3H, CH<sub>3</sub>);3.0(m, 2H, CH<sub>2</sub>); 3.5(s, 3H, OCH<sub>3</sub>); 3.7(dd, 2H, CH<sub>2</sub>); 3.8(dd, 2H, CH<sub>2</sub>); 3.97(m, 2H, CH<sub>2</sub>, methylene protons); 4.5(dd, 2H, CH<sub>2</sub>); 5.24(s, 1H, CH);6.10(s, 1H, thiazolidinone proton); 7.0-7.5(m, 8H, aromatic proton).

**I.R.:** IR spectra were recorded in KBr disc on Shimadzu FT-IR 8300 spectrophotometer.

3318(NH);1714,1697 and 1649 (C=O).

**Mass:** Mass spectra were recorded on Water-Macromass Quattro-III mass spectrometer.

Mass (m/z) 605 (M+1)

**Compound (3I):**

**(DMSO) δ ppm:**1.06 (t, 3H, CH<sub>3</sub>);2.2(s, 3H, CH<sub>3</sub>); 2.9(m, 2H, CH<sub>2</sub>);3.5(s, 3H, OCH<sub>3</sub>); 3.7(dd, 2H, CH<sub>2</sub>); 3.8(dd, 2H, CH<sub>2</sub>); 3.97(m, 2H, CH<sub>2</sub>, methylene protons); 4.5(dd, 2H, CH<sub>2</sub>); 5.27(s, 1H, CH);6.18(s, 1H, thiazolidinone proton); 7.0-7.5(m, 8H, aromatic proton); 8.4 9(s, 1H, N-H)

**(DMSO+D<sub>2</sub>O) δ ppm:**1.09 (t, 3H, CH<sub>3</sub>);2.5(s, 3H, CH<sub>3</sub>); 3.0(m, 2H, CH<sub>2</sub>);3.5(s, 3H, OCH<sub>3</sub>);3.7(dd, 2H, CH<sub>2</sub>); 3.8(dd, 2H, CH<sub>2</sub>); 3.97(m, 2H, CH<sub>2</sub>, methylene protons); 4.5(dd, 2H, CH<sub>2</sub>); 5.24(s, 1H, CH);6.10(s, 1H, thiazolidinone proton); 7.0-7.5(m, 8H, aromatic proton).

**I.R. (cm<sup>-1</sup>):** 3298(NH); 1726, 1684 and 1656(C=O).

**Mass:** Mass (m/z) 648.9 (M+1)

**Compound: 3h**

**(CDCl<sub>3</sub>) δ ppm:**1.19 (t, 3H, CH<sub>3</sub>);2.38(s, 3H, CH<sub>3</sub>); 3.0(m, 2H, CH<sub>2</sub>);3.6(s, 3H, OCH<sub>3</sub>); 3.7(dd, 2H, CH<sub>2</sub>); 3.8(dd, 2H, CH<sub>2</sub>); 3.97(m, 2H, CH<sub>2</sub>, methylene protons); 4.5(dd, 2H, CH<sub>2</sub>); 5.4(s, 1H, CH);5.8(s, 1H, thiazolidinone proton); 7.0-8.2(m, 8H, aromatic proton); 8.4 9(s, 1H, N-H)

**(CDCl<sub>3</sub>+D<sub>2</sub>O) δ ppm:**1.09 (t, 3H, CH<sub>3</sub>);2.5(s, 3H, CH<sub>3</sub>);3.0(m, 2H, CH<sub>2</sub>);3.5 (s, 3H, OCH<sub>3</sub>);3.7(dd, 2H, CH<sub>2</sub>); 3.8(dd, 2H, CH<sub>2</sub>); 3.97(m, 2H, CH<sub>2</sub>, methylene protons); 4.5(dd, 2H, CH<sub>2</sub>); 5.24(s, 1H, CH);6.10(s, 1H, thiazolidinone proton);7.0-8.2(m, 8H, aromatic proton).

**I.R. (cm<sup>-1</sup>):** 3320(NH); 1703, 1684 and 1655(C=O).

**Mass:** Mass (m/z) 616 (M+1)

**Compound-3f**

**(CDCl<sub>3</sub>) δ ppm:**1.18 (t, 3H, CH<sub>3</sub>);2.38(s, 3H, CH<sub>3</sub>); 3.1(m, 2H, CH<sub>2</sub>);3.6(m, 5H, OCH<sub>3</sub>-CH<sub>2</sub>); 3.8(dd, 2H, CH<sub>2</sub>); 3.97(m, 2H, CH<sub>2</sub>, methylene protons); 4.5(dd, 2H, CH<sub>2</sub>); 5.4(s, 1H, CH);6.1(s, 1H, thiazolidinone proton);7.0-7.4(m, 7H, aromatic proton); 7.5(s, 1H, N-H)

**I.R.:** IR spectra were recorded in KBr disc on Shimadzu FT-IR 8300 spectrophotometer.

**(3f) (cm<sup>-1</sup>):**3334(N-H),1725,1697.7 and 1652.3(C=O).

**Mass:** Mass (m/z) 639 (M+1)

**Antimicrobial activity**

Antimicrobial screening was done by using cup plate method (38-39) concentration of 100µg/ml. The compounds were evaluated for antibacterial activity against *Bacillus subtilis* gr +ve, *Pseudomonas aeruginosa* gr -ve, *Staphylococcus aureus* gr +ve, *Escherichia coli* gr -ve and antifungal activity against *Aspergillus niger*, *Aspergillus Flavus*, *Curvularia*, *Alternaria*. DMSO was used as solvent control. The results of antimicrobial data are summarized in **Table 2**. All compounds show the moderate to good activity against bacterial and fungal strain.

**Table II: Antimicrobial screening of Compounds (3a-i)**

Products	Bacteria				Fungi			
	(Zone of Inhibition in mm)				(Zone of Inhibition in mm)			
	A	B	C	D	E	F	G	H
I	12	16	12	---	---	17	---	14

II	11	12	13	---	---	14	16	17
III	12	18	21	---	14	---	16	---
IV	12	20	14	15	---	---	17	13
V	15	21	12	14	---	13	17	18
VI	12	16	13	---	---	---	15	17
VII	15	12	14	11	14	17	---	18
VIII	14	17	11	19	15	---	21	---
IX	14	11	21	10	---	13	---	14
X	11	11	14	18	12	---	17	---

A= *Bacillus subtilis* gr +ve, B= *Pseudomonas aeruginosa* gr -ve, C= *Staphylococcus aureus* gr +ve, D= *Escherichia coli* gr -ve, E= *Aspergillus niger*, F= *Aspergillus Flavus*, G= *Curvularia*, H= *Alternaria*

**CONCLUSION**

In conclusion, here we have reported some novel 4-thiazolidinone were synthesized via condensation of amlodipine Schiff bases and mercaptopropionic acid in dry benzene at refluxing temperature. The newly synthesized 4-thiazolidinone were confirmed by spectral analysis and further evaluated for their antimicrobial activity. The antibacterial and antifungal activity revealed that most of the compounds showed moderate to good activity.

**Acknowledgement**

The authors are thankful to Principal Yeshwant College, Nanded for providing lab facilities for the research work and also to the IICST Hyderabad for spectral analysis

**REFERENCES:**

1. a.Kucukguzel, A.; Kocatepe, G.; Clercq, E. De; Sahin, *Eur.J.Med.Chem.*, 41, **2006**, 353.
2. Tenorio, R.P.; Carvalho, C. S.; Pessanha, Lima, *Bioorg.Med.Chem. Lett.*, 15 **2005**,2575. c. Bonde, C.G.; Gaikwad, N.J. *Bioorg.Med.Chem.*, 12, **2004**, 2151.
3. Kucukguzel, S.G.; Oruc, E. E.; Rollas, Sahin S.F.; Zek, A.*Eur. J. Med Chem.*, **2002**.
4. Kucukguzel, S.G.; Oruc, E. E.; Rollas, Sahin S.F.; Zek, A.*Eur. J. Med Chem.*, 7, **2002**,197.
5. Pandeya, D.; Nair, K.B.; *Die Pharmazie*48, **1993**,414.
6. Geies, A. A.; Bakhite E.A.; El-Kashef, H.S. *Die Pharmazie.*, 53,**1998**,686.
7. Eid, A.I.; Ragab, F.A.; El-Ansary, S.L.; Gazayerly, S.M.; Mourad, F.E. *Arch. Pharm.* 32,**1994**, 211.
8. Kocabalkanli, A.; Ates, O.; Otuk, G. *Arch. Pharm. Med. Chem.*, 35, **2001**, 334.
9. Giri, S.; Shukla, A.K.; Nizamuddin, *J. Indian Pharm. Sci.*, 52, **1990**, 108.
10. Jagdees babu.V. Saritha.M. Sreenvasu, K.K.Reddy, *J.Pharmacy Research*, 4(5), **2011**, 1553-1555.
11. Deepak Pareek,M.Chaudhary,Pawan,K.Parek,Ravi, *Der Pharmacia*,2(1) **2011**,170-181.
12. Argyropoulou.I.A.Geronikaki, P.Vicini*Arkivoc*, 4,**2009**,89.
13. Cesur, N.; Cesur, Z.; Ergenc, N.; Uzun, M.; Kiraz, M.; Kasimoglu O.; Kaya, D.; *Arch. Pharm.*,32,**1994**,271.
14. Karali, N.; Ilhan, E.; Gursoy, A.; Kiraz, M.; *Farmaco.*, 53,**1998**,346.
15. Fahmy, H.T.Y. *Boll. Chim. Farmaco***2001**, 140, 422.
16. Capan, G.; Ulusoy, N.; Ergenc, N.; Kiraz, M. *Monatsh. Chem.*, 130, **1999**, 1399.
17. Kandeel, M.M.; El-Latif, H. A. *Bull. Fac. Pharm. Cairo Univ.*, **2001**, 39, 1; *Chem. Abstr.* **2001**, 135, 5582
18. Ergenc N.; Capan, G. *Farmaco*49, **1994**,133.
19. Ulusoy, N.; Ergenc, N.; Ekinci, A.C.; Ozer, H. *Monatsh. Chem.*, **1996**, 127, 1197.
20. Capan, G.; Ergenc, N.; Ekinci, A.C.; Vidin, A. *Farmaco*51, **1996**,729.
21. Ragab, F. A.; Eid N.M.; El-tawab, H.A. *Pharmazie*52, **1997**,926.
22. Bhatt, J.; Shah, B.R.; Shah, H.P.; Trivedi, P.B.; Undavia N.K.; Desai, N.C. *Indian J. Chem.*, 33B,**1994**, 189.
23. Guduru, V.; Hurh, E.; Dalton J. T.; Miller, D. D. *J. Med. Chem.*, 48, **2005**, 2584.
24. Kachhadia, V. V.; Patel, M. R.; Joshi, H. S. *J. Serb. Chem. Soc.*, 70, **2005**,153.
25. Babaoglu, K.; Page, M.A.; Jones, V.C.; Mc Neel, M.R.; Dong, C.; Naismith, J.H.; Lee, R.E.*Bioorg. Med. Chem. Lett.*, 13, **2003**,322.
26. Bhat A. R.; Shetty, S. J. *Indian Pharm. Sci.*, **1987**, 194.
27. Ulusoy, N. *Arzneim-Forsch/Drug.Res.*,52,**2002**, 565.
28. Bukowski, L.; Janowiec, M.; Zwolskawkiek Z.; Andzejc, Z. Z.; *Pharmazie*,53,**1998**, 373.
29. Kok,S.H.,Chai C.H., C.W.Vuen, *Bioorg.Med. Chem.*, 16, **2008**, 3626.
30. Murugesan.V.Y.S.Prabhakar,S.B.Katti,*J.Mol.Graph.Model*, 27,**2009**,735.
31. Anders, C. J.; Bronson, J. J.; Andrea, S.V.; Deshpande, M.S.; Falk, P.J.; Grant-Young, K.A.; Harte, E. W.; Ho, H.T.; Misco, P. F.; Robertson, J.G.; Stock, D.; Sun, Y.; Walsh, A.W. *Bioorg. Med. Chem. Lett.*, 10, **2000**,715.

30. Parmeswarm M.K., Thengungal R.K, *Acta pharma*, 59, **2009**,159.
31. Mahran, M.A.; El-Nassy, S.M.F.; Allam, S.R. *Pharmazie*, 58, **2003**, 527.
32. Suzuki, M.; Morita, K.; Yukioka, H.; Miki, N.; Mizutani, A.; *J. Pestic. Sci.*28, **2003**, 37.
33. El-Ansary, A.K.; Omar, A.H.;Bull. Fac. Pharm. Cairo Univ. **2001**, 39, 17;*Chem. Abstr.*,136, **2001**, 216712h.
34. Schenone, S.; Bruno, O.; Ranise, A.; Bondavalli, F.; Filippeli, W.; Falcone, G.; Giordano, L.; Vitelli, M.R.,*Bioorg. Med. Chem.*, 9, **2001**, 2149.
35. Barreca, L.M.; Chimirri, A.; Luca, L.D.; Monforte A.; Monforte, P. *Bioorg. Med. Chem Lett.*, 11,**2001**, 1793.
36. Venkatesh P, S.N.Pandya, *Inter.J.Chem. Tech Res*, 1(4) **2009**, 1354.
37. Rajeev B.,V.Kumar,S.M.Shantakumar, *Asian J.Chem*,21 (9), **2009**,6951.
38. Seely HW and Van Demark PJ. *Microbes in Action: A Laboratory Manual of Microbiology* DB Taraporewala Sons and Co. Bombay 1975; 55.
39. 22. Bantý AL. *The Antimicrobial Susceptability Test: Principle and Practice* Ed. by Illus Lea and Febiger (Philadelphia, PA, USA) 1976; 180